$107.14
1.15% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Jazz Pharmaceuticals Plc Stock price

$107.14
-4.23 3.80% 1M
-10.05 8.58% 6M
-15.86 12.89% YTD
-29.42 21.54% 1Y
-29.79 21.76% 3Y
-19.32 15.28% 5Y
-63.71 37.29% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-1.25 1.15%
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Key metrics

Market capitalization $6.62b
Enterprise Value $10.43b
P/E (TTM) P/E ratio 19.14
EV/FCF (TTM) EV/FCF 9.98
EV/Sales (TTM) EV/Sales 2.67
P/S ratio (TTM) P/S ratio 1.69
P/B ratio (TTM) P/B ratio 1.76
Revenue growth (TTM) Revenue growth 3.91%
Revenue (TTM) Revenue $3.91b
EBIT (operating result TTM) EBIT $650.27m
Free Cash Flow (TTM) Free Cash Flow $1.04b
Cash position $1.98b
EPS (TTM) EPS $5.60
P/E forward 13.34
P/S forward 1.64
EV/Sales forward 2.58
Short interest 4.36%
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
84%
Hold
16%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,910 3,910
4% 4%
100%
- Direct Costs 1,032 1,032
7% 7%
26%
2,878 2,878
8% 8%
74%
- Selling and Administrative Expenses 685 685
11% 11%
18%
- Research and Development Expense 895 895
24% 24%
23%
1,298 1,298
12% 12%
33%
- Depreciation and Amortization 648 648
6% 6%
17%
EBIT (Operating Income) EBIT 650 650
18% 18%
17%
Net Profit 395 395
557% 557%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
3 days ago
Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatment on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) DUBLIN , Sept. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will pres...
Neutral
PRNewsWire
4 days ago
DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rul...
Neutral
PRNewsWire
5 days ago
DUBLIN , Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") to ...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today